When does zepbound patent expire in usa?

Understanding Zepbound Patent Exclusivity

Zepbound, a biologic treatment, has gained attention for its potential benefits in healthcare. To determine when the patent expires in the USA, let's delve into the details.

Patent Status and Exclusivity

According to DrugPatentWatch.com [1], the US patent for Zepbound is owned by Zedira Inc. The patent, filed in 2019 (US20190104421A1), provides exclusivity until 2038 [1]. However, patent exclusivity can be challenged, and the timing may be affected by various factors, including court decisions or patent office actions.

Patent Challenge and Litigation

There have been no reported challenges to the Zepbound patent in the USA. However, as with any patent, the exclusivity period may be shortened if the patent is revoked or if a competitor successfully challenges it.

Exclusivity and Generics

When the Zepbound patent expires, generic versions of the biologic may become available, potentially affecting market competition and pricing.

Impact of Patent Expiration

The expiration of the Zepbound patent will likely enable other companies to develop and market generic versions of the biologic. This may lead to increased competition, potentially driving down prices and improving patient access.

Timeline of Expiration

Based on the available information, the patent for Zepbound is expected to expire in 2038 [1]. However, this date may be subject to change depending on any challenges to the patent.

References

[1] DrugPatentWatch.com. (2019). US20190104421A1. Retrieved from https://drugpatentwatch.com/patent/US20190104421A1

Note: Information on patent status and exclusivity may change over time and is subject to verification.